Defense Advanced Research Projects AgencyTagged Content List

Prevention and Therapy

Biomedical technologies designed to thwart initial infection or injury, or enable faster healing afterward

Showing 50 results for Therapy RSS
The Dialysis-Like Therapeutics (DLT) program aims to support force protection and military readiness by improving critical care in low-resource environments and delivering a new tool for rapid response to emerging infectious disease threats. DLT specifically addresses a life-threatening blood infection known as sepsis, but DARPA is working to expand the DLT technology to also mitigate threats from harmful bacteria, viruses, fungi, and toxic agents in the blood.
With a focus on wounded warriors and facilitating their return to military service, the Hand Proprioception and Touch Interfaces (HAPTIX) program is pursuing key technologies to enable precision control of and sensory feedback from sensor-equipped upper-limb prosthetic devices. If successful, the resulting system would provide users near-natural control of prosthetic hands and arms via bi-directional peripheral nerve implants. The program has a strong focus on technology handoff and aims to create and transition clinically relevant technology in support of wounded warriors suffering from single or multiple limb loss.
The In Vivo Nanoplatforms (IVN) program supports military readiness through the development of in vivo sensing technologies and therapeutics that facilitate optimal health and performance in individual warfighters. The program pursues technologies that provide early indication of physiological abnormalities or illness that can be proactively addressed with therapeutics or supportive care.
Viral pathogens pose a continuous and shifting biological threat to military readiness and national security overall in the form of infectious disease with pandemic potential. Today’s limited vaccines and other antivirals are often circumvented by quickly mutating viruses that evolve to develop resistance to treatments that are carefully formulated to act only specific strains of a virus.
07/10/2015
The White House announced the BRAIN initiative in April 2013. Today, the initiative is supported by several federal agencies as well as dozens of technology firms, academic institutions, scientists and other key contributors to the field of neuroscience. DARPA is supporting the BRAIN initiative through a number of programs, continuing a legacy of DARPA investment in neurotechnology that extends back to the 1970s.